Event Details
Unspecified
Description
Intercept Pharmaceuticals IPO
Participants (2)
| Name | Type | Mentions | |
|---|---|---|---|
| NLV-II | person | 0 | View Entity |
| ICA | organization | 1597 | View Entity |
Source Documents (1)
HOUSE_OVERSIGHT_024046.jpg
This document appears to be page 35 of a confidential investment memorandum for a fund named NLV-III (likely New Leaf Venture Partners). It outlines the fund's track record with previous investments (NLV-II) in companies like Array, Acadia, and Intercept Pharmaceuticals, highlighting successful exit multiples. The text details the investment thesis for NLV-III, focusing on targeted biopharmaceutical therapies and biomarker-guided programs that benefit patients, physicians, payers, and pharmaceutical companies. The document bears a House Oversight Committee stamp.
Related Events
Events with shared participants
Acquisition of Interlace Medical by Hologix
Date unknown • N/A
Mexican government released list of 38 approved OTC cannabis products
2018-11-01 • Mexico
Projected legalization of cannabis for adult-use purposes
2019-01-01 • Mexico
Supreme Court decision regarding the broadcasting of Carlin's routine on Pacifica radio.
Date unknown • USA
Arizona Republican Party enacts a resolution declaring the US a 'Christian Nation'.
Date unknown • Arizona
First Iraq War
1990-01-01 • Iraq
Set up a Family Assistance Hotline within 10 days via an outsourcer
2005-01-01 • USA
Formation of Saudi American Bank
1980-01-01 • Saudi Arabia
FDA accepted GW Pharmaceuticals’ New Drug Application (NDA) for the cannabis-derived drug Epidiolex.
2017-10-01 • USA
Fundraising campaign in Saudi Arabia for Al Quds uprising (Intifada)
2000-01-01 • Saudi Arabia
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein event